Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
|
|
First Wave BioPharma, Inc. (AZRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 10/10/2023 |
8-K/A
| Quarterly results |
| 10/06/2023 |
4
| Romano Sarah (CFO) has filed a Form 4 on First Wave BioPharma, Inc.|
Txns:
| Sold 1,676 shares
@ $0.29, valued at
$486 |
|
| 10/06/2023 |
4
| SAPIRSTEIN JAMES (President and CEO) has filed a Form 4 on First Wave BioPharma, Inc.|
Txns:
| Sold 2,764 shares
@ $0.29, valued at
$801.6 |
|
| 10/02/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 10/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/25/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/21/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 07/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/13/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/13/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/11/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/07/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 07/05/2023 |
4
| Romano Sarah (CFO) has filed a Form 4 on First Wave BioPharma, Inc.|
Txns:
| Sold 1,977 shares
@ $1.54, valued at
$3k
|
|
| 07/05/2023 |
4
| SAPIRSTEIN JAMES (President and CEO) has filed a Form 4 on First Wave BioPharma, Inc.|
Txns:
| Sold 3,349 shares
@ $1.54, valued at
$5.2k
|
|
| 06/28/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: __________ Initial Exercise Date: June 13, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time at any time on or after June 13, 2023 and on or prior to 5:00 p.m. on June 13, 2028 but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to _____ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .           Definitions . In addit...",
"Annex A – Representations and Warranties",
"First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market BOCA RATON, Fla., June 13, 2023 -- First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,681,667 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.15 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.4 million, before deducting financial ..." |
|
| 05/15/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/15/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/21/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
4
| Romano Sarah (CFO) has filed a Form 4 on First Wave BioPharma, Inc.|
Txns:
| Sold 1,975 shares
@ $2.5, valued at
$4.9k
|
|
| 04/05/2023 |
4
| SAPIRSTEIN JAMES (President and CEO) has filed a Form 4 on First Wave BioPharma, Inc.|
Txns:
| Sold 3,347 shares
@ $2.5, valued at
$8.4k
|
|
| 04/04/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 04/04/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/28/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/27/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/23/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 03/21/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/20/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
|
|
|